// App-Quantinova.ai

: Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).

Researchers

Presenter

  • Di Maria Jiang

Principal Investigators

  • Michael Donald Brundage

  • Christopher Sweeney

  • Karim Fizazi

  • Joaquim Bellmunt

  • David J. Vaughn

  • Thomas Powles

  • Nathan Perlis

  • Girish S. Kulkarni

  • Srikala S. Sridhar

Medical Centers

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Division of Cancer Care & Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, Canada

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Pennsylvania, Philadelphia, PA

  • Barts Cancer Institute, Royal Free NHS trust, St. Bartholomew’s Hospital, London, United Kingdom

  • Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

Locations

  • Canada

  • United States

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Prostate cancer

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved